FogPharma is a drug discovery company that aims to overcome the limitations of current precision medicines by developing a new class of drugs called HeliconTM peptides. These peptides combine the broad targeting power of monoclonal antibodies with the cell-penetrating ability of small molecules, allowing them to drug nearly all human disease drivers with unrivaled speed and scalability. The company is supported by a unique syndicate of private and institutional investors and collaborates with world-leading experts and cancer patients to pioneer a unique approach toward conquering cancer.